Novel Left Atrial Appendage Closure
Atrial Fibrillation patient
Atrial Fibrillation - AF
Left Atrial Appendage - LAA
Left Atrium - LA
Each year, 33 million people worldwide suffer a stroke, 20% of which are caused by Non Valvular Atrial Fibrillation (NVAF), a life-threatening heart rhythm disease.
In AF, blood clots are formed in the LAA, a small sac in the wall of the left atrium of the heart.
90% of strokes in NVAF patients are caused by migration of these clots to the brain.
Due to the LAA’s complex structure, it is difficult to close it completely by the current marketed devices and blood clots can still leak to the brain. Another risk of these devices is the potential formation of device-related thromboembolism because of foreign material implants that are left in the heart.
The Append Medical solution is in pre-clinical in-vivo trials phase. It is intended to become a differentiated solution in the LAA closure market, which has been estimated to reach $25B within several years. This is the second-fastest growing segment of the medical device market, with potential sales of $500M in 2019.
CEO & Founder
R&D Manager
Co-Founder & Consultant
Inventor & Advisor
Head of Heart Surgery Department
Sheba Medical Center
Chairman of the SAB
Director of the Cardiovascular Center
Frankfurt, Germany
Medical Advisor
Head of Structural Heart Disease Service
Interventional Cardiology
Tel Aviv Sourasky Medical Center
For more information please contact zachi.berger@appendmedical.com
Append Medical is a member of MEDX Xelerator, a medtech incubator backed by Boston Scientific, Intellectual Ventures, MEDX Ventures and Sheba Medical Center.